BlossomHill Therapeutics, Inc. Common Stock (BLSM)
PHARMACEUTICAL PREPARATIONS
BlossomHill Therapeutics, Inc. Common Stock (BLSM) is listed on Nasdaq, where it has traded since August 7, 2026.
- Listed On
- Nasdaq
- Listed Since
- August 7, 2026
- Employees
- 69
- Market Cap
- $472M
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Institutional ownership
In 13F filings for the quarter ended September 30, 2026, 6 institutions reported holding BLSM, with 1.3 million shares worth $23.3 million in aggregate. The largest reported holder was FMR, with 1.0 million shares worth $19.1 million. Of the 5 largest holders listed below, all 5 opened new positions in BLSM during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 1,027,293 | $19M | New position |
| Geode Capital Management | 119,176 | $2M | New position |
| Monashee Investment Management | 80,000 | $1M | New position |
| Squarepoint Ops | 23,150 | $432K | New position |
| Citigroup | 1,279 | $24K | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is BLSM?
BlossomHill Therapeutics, Inc. Common Stock (BLSM) is listed on Nasdaq, where it has traded since August 7, 2026.
Who are the largest institutional holders of BLSM?
In 13F filings for the quarter ended September 30, 2026, the largest reported holders of BLSM were FMR, Geode Capital Management and Monashee Investment Management.
How many institutions own BLSM?
6 institutions reported a position in BLSM for the quarter ended September 30, 2026, worth $23.3 million in total.
Did institutions buy or sell BLSM last quarter?
Of the 5 largest reported holders, all 5 opened new positions in BLSM during the quarter. Every reported holder and its change is on the SentiSense ownership page for BLSM.
Every reported institutional holder, plus insider and congressional trades in BLSM, on SentiSense.